Alnylam's Vutrisiran Shows Positive Results in Phase 3 Heart Disease Study, Stock Surges 30%

Jun 24, 2024, 11:15 AM

Alnylam Pharmaceuticals announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, a treatment for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). The late-stage study achieved statistical significance on primary and all secondary endpoints in both overall and monotherapy populations. Vutrisiran demonstrated a reduction in the risk of death and recurrent cardiovascular complications. This success likely paves the way for vutrisiran to become the first RNA silencing therapy on the market for ATTR amyloidosis with cardiomyopathy. The positive results have also led to a significant increase in Alnylam's stock price, which surged by 30%.